Home / Optimizing spray formation of low GWP metered dose inhalers – unlocking product performance understanding

Optimizing spray formation of low GWP metered dose inhalers – unlocking product performance understanding

November 27, 2023

Thank you for attending the webinar for Benjamin Myatt, R&D Staff Scientist at Kindeva, and Daniel Duke, Senior Lecturer in the Department of Mechanical & Aerospace Engineering at Monash University. This session explored key issues related to spray formation and product development for MDI using green propellants.

Key Takeaways:

  • The differences in pMDI propellant properties and implications of low-GWP options for droplet production and product performance
  • A range of investigations undertaken, including novel high-speed imaging and X-ray diagnostics and pharmacopeial performance experiments, to explore the impact of switching to green propellants in pMDI products
  • A summary of key findings and insights to enable tuning of low-GWP pMDI product performance

Download The Presentation

Fields marked with a * are required.

About the author

Ben Myatt is a Kindeva R&D engineer, developing and evaluating next-generation green pMDI propellants, formulations and test methodologies to improve patient outcomes and reduce the industry’s impact on the planet.

R&D Staff Scientist, Loughborough

Ben Myatt

Read bio

Related resources

Explore our other resources to discover valuable insights on the latest trends in drug delivery.

HFA152a green propellant capabilities

With evolving regulations and a growing push for sustainability, switching pressurized metered-dose inhalers (pMDIs) to green propellants is becoming increasingly essential. One of the most promising low global warming potential (GWP) options is HFA152a. In this white paper, we share insights on transitioning to HFA152a. Download your copy to discover: An overview of sustainability regulations […]

Learn More

Leading the way in low-GWP propellants

As regulations surrounding inhalation device sustainability evolve, we help you streamline the process of transitioning to low global warming potential (GWP) propellants. Clinical supply for green propellants HFA152a and HFO1234ze is already available, with commercial scale available this year and plans for further expansion. Download this information sheet to dive deeper into our low-GWP propellant […]

Learn More

Opportunities and considerations for inhaled biologics

Respiratory biologics is an emerging area in pharmaceutical development, accounting for approximately 10% of biologics currently in the pipeline. These innovative treatments offer significant benefits across various therapeutic areas. Gain deeper insights into the development of inhaled biologics with this comprehensive presentation by experts from Kindeva Drug Delivery, Aerogen Pharma, and Cystetic Medicines. Highlights include: […]

Learn More

Pulmonary & nasal delivery capabilities 

Get an overview of our pulmonary & nasal delivery capabilities, including:  Customized approach to determining the right device for your drug  Pulmonary & nasal platform technologies: pressurized metered-dose inhaler (pMDI), dry power inhaler (DPI), soft-mist inhaler (SMI), nebulizer, and nasal spray  Green propellant innovations  Experience bringing complex generics to market  Expansive capabilities across state-of-the-art facilities […]

Learn More

Optimizing spray formation of low GWP metered dose inhalers – Unlocking product performance understanding

In response to growing concerns about sustainability, switching to more environmentally friendly pMDI propellants has become a high priority for the pharmaceutical industry. Since inhalation devices contribute 3% of global emissions, this is an important step. In addition to being a part of a greener future, transitioning to a low GWP propellant now positions companies […]

Learn More

Challenges in analytical aerosol methods for high payload inhalation products

Access Now

Learn More

Missed ss at DDL? Unlock pulmonary & nasal insights with our presentations 

Kindeva Drug Delivery presented cutting-edge advancements in pulmonary & nasal development and manufacturing at the Drug Delivery to the Lungs (DDL) conference on December 6-8, 2023. Across eight posters and podium presentations, we highlighted strategies for switching to green propellant formulations while preserving product performance, among a variety of other topics. If you missed any […]

Learn More

The pMDI dilemma: managing patient needs, human health, and the planet

Learn More

Green propellants: The impact of proposed regulations

Learn More

Let’s transform tomorrow together

Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.